BRAF and melanoma: Our data provide the first in vitro observation that BRAF/MEK inhibitors decrease TF in BRAFv600e mutated melanoma cells thus inhibiting the coagulation cascade, adding one more piece of evidence to the complex relationship between coagulation and cancer.